Mark Anderson

Dr. Anderson leads GenPro’s strategy and its execution with our biopharma collaboration partners. He is an oncology R&D leader with over 25 years of experience in the biotechnology and pharmaceutical industries. He earned his B.S .degree in Biochemistry from Iowa State University in Ames and received his Ph.D. in Biological Chemistry from the University of Michigan in Ann Arbor, followed by postdoctoral training at Merck Research Laboratories in West Point, Pennsylvania He is a cancer biologist and experienced drug developer with discovery and development of antibody-based therapeutics as his primary area of expertise.

Dr. Anderson has extensive large pharma experience, most recently with J&J (Janssen/Centocor), successfully initiating projects, developing agents utilizing novel and complex platforms, leading discovery and cross-functional compound development teams, and setting overall discovery and development strategy. He led teams that have taken multiple antibody based anti-cancer therapeutics to the NME stage, with several progressing to IND and clinical evaluation. He has also served as an adviser to life science focused venture capital firms, drug development accelerators and start-ups, and public biotechnology companies. In addition to his focus on cancer biology Dr. Anderson has expertise in the fields of biomarker discovery and development, T-cell redirection, immuno-oncology, and innate immune function.